Trial Profile

A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jan 2024 Status changed from recruiting to completed.
12 Dec 2023 Results (Data cutoff March 28, 2023;n=36)evaluating efficacy and safety of crizanlizumab after 26 weeks of treatment in patients with SCD-related priapism, presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Jun 2023 Interim results (data cut-off, March 8, 2022, n=24) assessing the efficacy and safety ofcrizanlizumab in SCD patients with priapism presented at the 28th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com